Inhibition of homologous recombination repair by Mirin in ovarian cancer ameliorates carboplatin therapy response in vitro
Mutagenesis · 2025
DOI: 10.1093/mutage/gead036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mutagenesis, 2025. Verfasst von Josef Horak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology of Cancer, Institute of Experimental Medicine Czech Academy of Sciences (CAS), 142 20 Prague, Czech Republic. Hauptthemen laut MEDLINE: Carboplatin, Ovarian Neoplasms, Recombinational DNA Repair, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Czech Science Foundation.
Abstract (Originalsprache)
Chemoresistance poses one of the most significant challenges of cancer therapy. Carboplatin (CbPt) is one of the most used chemotherapeutics in ovarian cancer (OVC) treatment. MRE11 constitutes a part of homologous recombination (HR), which is responsible for the repair of CbPt-induced DNA damage, particularly DNA crosslinks. The study’s main aim was to address the role of HR in CbPt chemoresistance in OVC and to evaluate the possibility of overcoming CbPt chemoresistance by Mirin-mediated MRE11 inhibition in an OVC cell line. Lower expression of MRE11 was associated with better overall survival in a cohort of OVC patients treated with platinum drugs (TCGA dataset, P < 0.05). Using in vitro analyses, we showed that the high expression of HR genes drives the CbPt chemoresistance in our CbPt-resistant cell line model. Moreover, the HR inhibition by Mirin not only increased sensitivity to carboplatin (P < 0.05) but also rescued the sensitivity in the CbPt-resistant model (P < 0.05). Our results suggest that MRE11 inhibition with Mirin may represent a promising way to overcome OVC resistance. More therapy options will ultimately lead to better personalized cancer therapy and improvement of patients’ survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology of Cancer, Institute of Experimental Medicine Czech Academy of Sciences (CAS), 142 20 Prague, Czech Republic.
- Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic.
- Faculty of Science, Charles University, 128 00 Prague, Czech Republic.
- First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic.
- Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic.
- Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic.
ORCID-Profile: Petr Holy
Förderung
- Czech Science Foundation
Zitieren
APA
Horak, J., Vallusova, D., Cumova, A., Holy, P., Vodicka, P., & Opattova, A. (2025). Inhibition of homologous recombination repair by Mirin in ovarian cancer ameliorates carboplatin therapy response in vitro. Mutagenesis. https://doi.org/10.1093/mutage/gead036
Vancouver
Horak J, Vallusova D, Cumova A, Holy P, Vodicka P, Opattova A. Inhibition of homologous recombination repair by Mirin in ovarian cancer ameliorates carboplatin therapy response in vitro. Mutagenesis. 2025. doi:10.1093/mutage/gead036
BibTeX
@article{Horak2025,
author = {Horak, Josef and Vallusova, Dominika and Cumova, Andrea and Holy, Petr and Vodicka, Pavel and Opattova, Alena},
title = {Inhibition of homologous recombination repair by Mirin in ovarian cancer ameliorates carboplatin therapy response in vitro},
journal = {Mutagenesis},
year = {2025},
doi = {10.1093/mutage/gead036}
}
EUVIMED